Can TScan’s TSC-101 Phase 1 data justify a pivotal leap as TCRX stock falls?
TSC-101 produced rapid donor chimerism with a commercial-ready manufacturing process, but TScan must still prove that the cellular therapy prevents post-transplant relapse.
Pharma & Biotech